Zeynep GUNES OZUNAL, Yaprak DONMEZ CAKİL, Sena TEKİN, Esra SAGLAM, Ranan AKTAS

Metoclopramide increased cell proliferation in HepG2 cell line and sorafenib attenuated the effect

AbstractAim: Metoclopramide is an antiemetic drug used for treating postoperative or chemotherapy-induced emesis. Sorafenib is a kinase inhibitor drug and is approved for the treatment of advanced primary liver cancer, renal cell carcinoma, thyroid cancer, and acute myeloid leukemia. Hepatocellular cancer is a common cause of cancer-related death and its treatment may require coadministration of an antiemetic medication. The study aims to investigate the effect of metoclopramide on hepatocellular cancer cell proliferation alone or in combination with sorafenib.Material and Methods: Metoclopramide doses of 0.17 µM to 25 µM alone or in combination with sorafenib were administered to human hepatocellular cancer cell line, HepG2. Cell viability and proliferation test was used to determine the possible effects on proliferation. Hematoxylin and Eosin staining was performed to visualize the morphological effects of the treatments.Results: Metoclopramide doses of 0.58 µM, 25µM increased cell proliferation when compared to the control group. Metoclopramide combination groups with 9.9 µM sorafenib were compared with control and sorafenib groups. Each combination group was comparable with the control group.Conclusion: Metoclopramide increased proliferation in certain doses. Sorafenib inhibited the effect. Safety concerns about its use in hepatocellular cancer should be addressed in clinical trials.

PDF

___

1. Schulze-Delriu K. Drug therapy. Metoclopramide. N Eng J Med 1981;305:28-33.
2. Sharkey KA, MacNaughton WK. Gastrointestinal pharmacology. In: Brunton LL, Hilal-Dandan R, Knollman BC, eds. Goodman & Gilman’s: The Pharmacological Basis of Therapeutics. 13nd edition. New York: McGraw-Hill 2018;921-54.
3. Sanger GJ, Andrews PLR. A history of drug discovery for treatment of nausea and vomiting and the implications for future research. Front Pharmacol 2018;9:913.
4. Isola S, Adams N. Metoclopramide. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan. https://www.ncbi.nlm.nih.gov/books/ NBK519517/ access date: 24.03.2020
5. Balogh J, III DV, Asham EH, et al. Hepatocellular carcinoma: a review. J Hepatocell Carcinoma 2016;3:41-53.
6. Pitoia F, Jerkovich F. Selective use of sorafenib in the treatment of thyroid cancer. Drug Des Devel Ther 2016;10:1119-31.
7. Liu T, Ivaturi V, Sabato P, et al. Sorafenib dose recommendation in acute myeloid leukemia based on exposure-FLT3 relationship. Clin Transl Sci 2018;11:435-43.
8. Rimassa L, Danesi R, Pressiani T, et al. Management of adverse events associated with tyrosine kinase inhibitors: improving outcomes for patients with hepatocellular carcinoma. Cancer Treat Rev 2019;77:20-8.
9. Wallenborn J, Gelbrich G, Bulst D, et al. Prevention of postoperative nausea and vomiting by metoclopramide combined with dexamethasone: randomised double blind multicentre trial. BMJ 2006;333:324.
10. Rangwala F, Williams KP, Smith GR, et al. Differential effects of arsenic trioxide on chemosensitization in human hepatic tumor and stellate cell lines. BMC Cancer 2012;12:402.
11. Motlagh PB, Henriksson R, Grankvist K. Interaction of the antiemetics ondansetron and granisetron with the cytotoxicity induced by irradiation, epirubicin, bleomycin, estramustine, and cisplatin in vitro. Acta Oncol 1995;34:871-5.
12. Motlagh PB, Henriksson R, Grankvist K. Metoclopramide inhibits the cytotoxicity of cisplatin and enhances the cytotoxicity of epirubicin. Pharmacol Toxicol 1995;76:146-8.
13. Olsson AR, Hua J, Sheng Y, et al. Neutral metoclopramide induces tumor cytotoxicity and sensitizes ionizing radiation of a human lung adenocarcinoma and virus induced sarcoma in mice. Acta Oncol 1997;36:323-30.
14. Lybak S, Pero RW. The benzamide derivative metoclopramide causes DNA damage and inhibition of DNA repair in human peripheral mononuclear leukocytes at clinically relevant doses. Carcinogenesis 1991;12:1613-7.
15. Zerek-Melen G, Winczyk K, Kunert-Radek J, et al. Effects of metoclopramide on rat spleen lymphocyte proliferation. Biochem Biophys Res Commun 1990;171:1099-104.
16. Zou J, Li H, Huang Q, et al. Dopamine-induced SULT1A3/4 promotes EMT and cancer stemness in hepatocellular carcinoma. Tumour Biol 2017;39:1010428317719272.
17. Zhang L, Wu LL, Huan HB, et al. Activation of muscarinic acetylcholine receptor 1 promotes invasion of hepatocellular carcinoma by inducing epithelial-mesenchymal transition. Anticancer Drugs 2020.
18. Sachs HC and Committee On Drugs. The transfer of drugs and therapeutics into human breast milk: an update on selected topics. Pediatrics 2013;132:796- 809.
19. Sayin O, Gurgen SG, Umur N, et al. An examination of the effect of metoclopramide on proliferation signal molecules in newborn liver tissue. The J DEU Medical Faculty 2018;32:69-76.
20. Demirtas MS. Acute dystonic reaction due to metoclopramide use in a 9-year-old patient. Ann Med Res 2019;26:772-3.
21. Akgun FS, Karaarslan N, Yilmaz I, et al. Evaluation of the effect of apixaban on the primary intact intervertebral disc cell cultures. Ann Med Res 2019;26:2414-22.